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FIGURE 1 Active GLP-1 Levels During 75g-OGTT in
Non–Diabetes Mellitus Patients With or Without CAD
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Values are calculated as the mean  SD. CAD ¼ coronary artery
disease; GLP-1 ¼ glucagon-like peptide-1; OGTT ¼ oral glucose
tolerance test.
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7551.08 to 2.54; p ¼ 0.02) (C statistic without F-aGLP-1:
0.664; with F-aGLP-1: 0.705).
The present study is the ﬁrst to demonstrate
signiﬁcantly reduced plasma aGLP-1 levels in a fasting
state and during 75g-OGTT in CAD patients. Lower
aGLP-1 levels were signiﬁcantly correlated with the
presence of CAD. Furthermore, lower F-aGLP-1 levels
were associated with severe coronary plaque
complexity in CAD patients. These results suggested
that there may be a pathophysiological link between
endogenous aGLP-1 and CAD.
Although previous reports have demonstrated that
incretin-related drugs attenuated the development of
atherosclerotic lesions in animal models (2), a large
clinical study failed to demonstrate any beneﬁt of
dipeptidyl peptidase-4 inhibition on ischemic events
in patients with established disease (3). Further
studies are warranted to clarify clinical signiﬁcance of
GLP-1 in CAD.
In summary, plasma aGLP-1 levels were signiﬁ-
cantly reduced in CAD patients, and lower plasma
aGLP-1 levels were independently correlated with
the presence of CAD and coronary plaque com-
plexity. The gut-derived endogenous aGLP-1 may
have a signiﬁcant association with human coronary
atherosclerosis.Eiichi Akiyama, MD
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1317–26.Inﬂuence of Sex
on Mortality and
Perioperative Outcomes
in Patients Undergoing TAVRInsights From the FRANCE 2 RegistryTranscatheter aortic valve replacement (TAVR) is an
alternative to surgery for high-risk or inoperable pa-
tients (1). However, few data, with varied and
confusing follow-up timings, are available (2,3)
TABLE 1 Patient Characteristics and Outcomes
Female
(n ¼ 1,967)
Male
(n ¼ 2,005) p Value
Age, yrs 84.0  6.6 81.6  7.5 <0.001
Body mass index, kg/m2 25.7  5.4 26.3  4.5 <0.001
Logistic EuroSCORE, % 21.4  13.0 22.2  15.2 0.97
Clinical history
Coronary artery disease 918 (47.9%) 1341 (69.0%) <0.001
Chronic obstructive pulmonary disease 397 (20.3%) 503 (25.1%) 0.003
Peripheral vascular disease 278 (14.2%) 521 (26.1%) <0.001
Creatinine before procedure >200 mmol/l 120 (6.1%) 220 (11.0%) <0.001
Cerebrovascular disease 191 (9.8%) 198 (9.9%) 0.91
Echocardiographic ﬁndings
Mean gradient, mm Hg 51.0  17.7 45.4  14.8 <0.001
Effective oriﬁce area indexed, cm2/m2 0.4  0.2 0.4  0.2 0.041
Ejection fraction, % 56.6  13.3 50.1  14.3 <0.001
Transfemoral TAVI approach 1536 (78.7%) 1365 (68.4%) <0.001
Edwards Sapien/Medtronic CoreValve 73.2%, 26.8% 60.4%, 39.6% <0.001
Echocardiographic ﬁndings, post-procedural
Effective oriﬁce area indexed, cm2/m2 1.1  0.3 1.0  0.3 0.13
Ejection fraction, % 58.2  11.6 52.9  12.9 <0.001
Pulmonary artery pressure, mm Hg 40.5  12.1 41.2  13.2 0.31
Moderate to severe aortic regurgitation 196 (11.8%) 294 (17.1%) <0.001
Outcomes
Adverse events <24 h
Major and life-threatening bleeding 85 (4.3%) 38 (1.9%) 0.001
Major vascular event 90 (4.6%) 39 (1.9%) <0.001
Post-procedural pacemaker implantation (before 1 month)
PPI total 184 (9.3%) 257 (12.8%) <0.001
PPI in Medtronic CoreValve prosthesis 83 (15.8%) 145 (18.2%) 0.30
PPI in Edwards Sapien prosthesis 101 (17.0%) 112 (9.3%) 0.040
Combined safety endpoint at 1 month 448 (22.8%) 407 (20.3%) 0.058
Death
At 1 month
From any cause 187 (9.5%) 184 (9.2%) 0.27
From cardiovascular cause 125 (6.4%) 133 (6.6%) 0.35
From 1 month to 1 year
From any cause 193 (9.8%) 291 (14.5%) <0.001
From cardiovascular cause 95 (4.8%) 152 (7.6%) 0.004
At 1 year (cumulative)
From any cause 380 (19.3%) 475 (23.7%) 0.021
From cardiovascular cause 220 (11.2%) 285 (14.2%) 0.036
Values are mean  SD, or n (%).
PPI ¼ post-procedural pacemaker implantation; TAVI ¼ transcatheter aortic valve implantation.
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756concerning sex related differences in post-TAVR
patients.
We sought to clarify the independent impact of sex
on cardiovascular outcomes in patients who under-
went TAVR and were included in the FRANCE 2
(French Aortic National CoreValve and Edwards)
registry (1). The study design and procedures have
been described previously (1).
The 3,972 patients who underwent TAVR in French
centers between January 2010 and January 2012 were
prospectively included into the registry. Overall,
1,967 were women (49.5%).Quantitative and qualitative variables were
compared using unpaired Student t test or chi-
square test, respectively. Cox regression models
were applied for explaining 1-month and 1-month
to 1-year mortality, and the combined safety
endpoint that comprised a composite of all-cause
mortality, stroke, life-threatening bleeding, acute
renal failure, periprocedural myocardial infarction,
major vascular complication, and the need for
repeating the procedure at 1 month. We tested spe-
ciﬁc interactions between sex and either Euro-
SCORE, renal failure, coronary artery disease, or
moderate to severe post-procedural aortic regurgi-
tation. Signiﬁcant interactions were included into
the Cox models. Statistical signiﬁcance was set at
p < 0.05.
Women presented with fewer comorbidities but
similar logistic EuroSCORE (Table 1), exhibiting more
often a history of congestive heart failure (43.7% vs.
39.7%; p ¼ 0.001), but less often a history of angina
(14.5% vs. 17.0%; p ¼ 0.032).
The absolute 1-month mortality was similar in
men and women (Table 1). A signiﬁcant interaction
between sex and EuroSCORE was clearly distin-
guished, with a higher EuroSCORE proving predic-
tive of excessive mortality solely in male patients
(hazard ratio [HR]: 3.44 [95% conﬁdence interval
(CI): 1.77 to 6.69]; p < 0.001). In this model, female
sex was found to produce an HR of 2.59 [95% CI: 1.30
to 5.17] (p ¼ 0.013). The other independent pre-
dictors for 1-month mortality were as follows:
transapical approach (HR: 1.78 [95% CI: 1.10–2.87];
p ¼ 0.020); moderate to severe post-procedural
aortic regurgitation (HR: 2.46 [95% CI: 1.57–3.85];
p < 0.001).
Women presented with lower 1-year mortality
(19.3% vs. 23.7%; p ¼ 0.021). Independent predictors
of 1-month to 1-year mortality were female sex
(HR: 0.71 [95% CI: 0.57 to 0.88]; p < 0.002), age >85
years (HR: 1.29 [95% CI: 1.04 to 1.59]; p ¼ 0.020),
EuroSCORE (HR: 1.36 [95% CI: 1.09 to 1.68]; p¼ 0.006),
hostile thorax (HR: 1.42 [95% CI: 1.10 to 1.83];
p ¼ 0.007), New York Heart Association functional
class III or IV (HR: 1.43 [95% CI: 1.10 to1.86]; p¼0.008),
renal failure (HR: 1.86 [95% CI: 1.38 to 2.52]; p< 0.001),
and moderate to severe post-procedural aortic regur-
gitation (HR: 1.68 [95% CI: 1.32 to 2.16]; p < 0.001).
No signiﬁcant interaction was detected.
Female sex was not an independent predictor of
the composite safety endpoint (HR: 1.20 [95% CI:
0.99 to 1.46]; p ¼ 0.06). Female patients presented,
however, with higher rates of iliofemoral dissection
or rupture (5.6% vs. 2.2%; p < 0.001). Both female and
male patients displayed similar changes in New York
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757Heart Association functional class and low stroke
rates (3.1% vs. 2.2%; p ¼ 0.11).
The FRANCE 2 registry reported more frequent use
of post-procedural pacemaker implantation in men
(3), while more women had higher rates with the
balloon-expandable valve (Sapien, Edwards Life-
sciences, Irvine, California), which may illustrate the
impact of balloon expansion in smaller aortic roots.
After multiple adjustments, we found the male
sex to be a predictive factor of 1-month to 1-year
mortality. Our report is the ﬁrst large study to
corroborate such insight of the literature (2,3).
Although aortic stenosis affects both sexes equally
(4), the limited use of TAVR in female patients
(“only” 49.5% of the cohort) is somewhat confusing,
given their naturally longer life expectancy. This
paradox had already been conﬁrmed in valvular sur-
gery (5). Women should, in fact, receive a higher rate
of TAVR procedures, which could further enhance its
cost-effectiveness.
In conclusion, our study provides evidence of the
numerous imbalances in baseline characteristics and
outcomes that exist between sexes. The lower 1-year
mortality in women remained signiﬁcant after
adjustment for confounders. The logistic EuroSCORE
was not a good predictor of mortality and appeared
unsuitable for 1-month prognosis estimation in fe-
male patients. This underlines the usefulness of
drawing up a speciﬁc risk score for complications
and mortality in TAVR patients, notably one that
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by Dr. Fuster (1), which emphasizes that technological
advances are replacing medicine at the patient’s
bedside, instead of complementing it.
In 1964, Herbert Marcuse published a book that
became famous in the student movement of the 1960s:
One-Dimensional Man (2). According to the author,
modern society tends to control, suppress, or even
eliminate many aspects of human existence, such as
nature, art, or sexuality. In our technological civiliza-
tionman lives predominantly in 1 dimension, based on
production and consumption of waste, without the
possibility of resistance. The current diagnostic and
therapeutic approach, based largely on technology at
the expense of the enormous amount of information
and its effects that can result from personal interac-
tion between doctor and patient, leads us to believe
that patients are currently conﬁned to a single
dimension—that of medicine itself. Other dimensions
that play a signiﬁcant role in the pathogenesis and
prognosis of diseases, such as the psychological, so-
cial, economic, or spiritual, are in fact ignored.
It is clear that patients with myocardial infarction
show an increased prevalence of stress at work, in the
family, ﬁnancial stress, and stressful life events
compared with healthy controls (3). It is also clear that
depression increases the risk of developing ischemic
heart disease in previously healthy persons and is
associated with increased mortality after myocardial
infarction, although this relationship is attenuated—
but remains signiﬁcant—after adjusting for the
severity of the heart disease and other variables.
Anxiety in young people predicts subsequent cardio-
vascular events and worsens the prognosis in patients
with ischemic heart disease. More recently it has been
shown that acute emotional triggers, such as anger
attacks, can precipitate a myocardial infarction, an
